The Impact of DNA Repair Pathways in Cancer Biology and Therapy
Conflicts of Interest
References
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
- Taylor, E.M.; Lehmann, A.R. Conservation of eukaryotic DNA repair mechanisms. Int. J. Radiat. Biol. 1998, 74, 277–286. [Google Scholar] [PubMed]
- Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204. [Google Scholar] [CrossRef] [PubMed]
- Dietlein, F.; Thelen, L.; Reinhardt, H.C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014, 30, 326–339. [Google Scholar] [CrossRef] [PubMed]
- Manic, G.; Obrist, F.; Sistigu, A.; Vitale, I. Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol. Cell. Oncol. 2015, 2, e1012976. [Google Scholar] [CrossRef] [PubMed]
- Lord, C.J.; Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013, 19, 1381–1388. [Google Scholar] [CrossRef] [PubMed]
- Lim, J.S.J.; Tan, D.S.P. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers 2017, 9, 109. [Google Scholar] [CrossRef] [PubMed]
- Meek, D.W. Tumour suppression by p53: A role for the DNA damage response? Nat. Rev. Cancer 2009, 9, 714. [Google Scholar] [CrossRef] [PubMed]
- Reaper, P.M.; Griffiths, M.R.; Long, J.M.; Charrier, J.D.; Maccormick, S.; Charlton, P.A.; Golec, J.M.; Pollard, J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7, 428–430. [Google Scholar] [CrossRef] [PubMed]
- Bucher, N.; Britten, C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 2008, 98, 523–528. [Google Scholar] [CrossRef] [PubMed]
- Rundle, S.; Bradbury, A.; Drew, Y.; Curtin, N.J. Targeting the ATR-CHK1 axis in cancer therapy. Cancers 2017, 9, 41. [Google Scholar] [CrossRef] [PubMed]
- Roth, D.B.; Gellert, M. New guardians of the genome. Nature 2000, 404, 823–825. [Google Scholar] [CrossRef] [PubMed]
- Difilippantonio, M.J.; Zhu, J.; Chen, H.T.; Meffre, E.; Nussenzweig, M.C.; Max, E.E.; Ried, T.; Nussenzweig, A. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000, 404, 510–514. [Google Scholar] [CrossRef] [PubMed]
- Sishc, B.J.; Davis, A.J. The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers 2017, 9, 81. [Google Scholar] [CrossRef] [PubMed]
- Nikitaki, Z.; Pavlopoulou, A.; Holá, M.; Donà, M.; Michalopoulos, I.; Balestrazzi, A.; Angelis, K.J.; Georgakilas, A.G. Bridging Plant and Human Radiation Response and DNA Repair through an In Silico Approach. Cancers 2017, 9, 65. [Google Scholar] [CrossRef] [PubMed]
- Osama, M.; Sishc, B.J.; Saha, J.; Pompos, A.; Rahimi, A.; Story, M.D.; Davis, A.J.; Kim, D.W. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers 2017, 9, 66. [Google Scholar] [CrossRef]
- Schlaff, C.D.; Krauze, A.; Belard, A.; O’Connell, J.J.; Camphausen, K.A. Bringing the heavy: Carbon ion therapy in the radiobiological and clinical context. Radiat. Oncol. 2014, 9, 88. [Google Scholar] [CrossRef] [PubMed]
- Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931–947. [Google Scholar] [CrossRef] [PubMed]
- Diehn, M.; Cho, R.W.; Lobo, N.A.; Kalisky, T.; Dorie, M.J.; Kulp, A.N.; Qian, D.; Lam, J.S.; Ailles, L.E.; Wong, M.; et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458, 780–783. [Google Scholar] [CrossRef] [PubMed]
- Samaranayake, G.J.; Huynh, M.; Rai, P. MTH1 as a Chemotherapeutic Target: The Elephant in the Room. Cancers 2017, 9, 47. [Google Scholar] [CrossRef] [PubMed]
- Baumann, M.; Krause, M.; Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8, 545–554. [Google Scholar] [CrossRef] [PubMed]
- Chang, L.; Graham, P.; Hao, J.; Ni, J.; Deng, J.; Bucci, J.; Malouf, D.; Gillatt, D.; Li, Y. Cancer stem cells and signaling pathways in radioresistance. Oncotarget 2016, 7, 11002–11017. [Google Scholar] [CrossRef] [PubMed]
- Rivera, M.; Sukhdeo, K.; Yu, J. Ionizing radiation in glioblastoma initiating cells. Front. Oncol. 2013, 3, 74. [Google Scholar] [CrossRef] [PubMed]
- Annovazzi, L.; Mellai, M.; Schiffer, D. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. Cancers 2017, 9, 57. [Google Scholar] [CrossRef] [PubMed]
- Catto, J.W.; Meuth, M.; Hamdy, F.C. Genetic instability and transitional cell carcinoma of the bladder. BJU Int. 2004, 93, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Mouw, K.W. DNA Repair Pathway Alterations in Bladder Cancer. Cancers 2017, 9, 28. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nikolaev, A.; Yang, E.S. The Impact of DNA Repair Pathways in Cancer Biology and Therapy. Cancers 2017, 9, 126. https://doi.org/10.3390/cancers9090126
Nikolaev A, Yang ES. The Impact of DNA Repair Pathways in Cancer Biology and Therapy. Cancers. 2017; 9(9):126. https://doi.org/10.3390/cancers9090126
Chicago/Turabian StyleNikolaev, Anatoly, and Eddy S. Yang. 2017. "The Impact of DNA Repair Pathways in Cancer Biology and Therapy" Cancers 9, no. 9: 126. https://doi.org/10.3390/cancers9090126